Boceprevir and telaprevir: efficacy and side effects : what have we learned in 2013

F. Poordad

Pres.

 

Novel DAA’s combined with PEG/RIBA

H. Wedemeyer

Pres.

 

Simeprevir Overview: From IFN-Containing to IFN-Free Regimens

M. Beumont

Pres.

 

Management and monitoring of HCCi in the future era of DAA’s

M. Colombo

Pres.

 

The current challenges in treating cirrhotic patients

M. Bourliere

Pres.

 

Treating HCV genotype 2 & 3

C. Sarrazin

Pres.

 

Latest insights from NUC-containing regimens: what is the best partner molecule?

G. Dusheiko

Not availble

 

NUC sparing regimens : where do we stand

S. Zeuzem

Pres.

 

Update: Early investigational trials

P. Ferenci

Pres.

 

 
 
Virology Education -
a Medical Education company